BTIG Research initiated coverage of Solventum Corporation with a rating of Neutral
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/4/2024 | $70.00 | Neutral | Mizuho |
| 10/8/2024 | $82.00 | Buy | Stifel |
| 10/7/2024 | $71.00 | Neutral | Piper Sandler |
| 9/26/2024 | Peer Perform | Wolfe Research | |
| 9/5/2024 | Neutral | BTIG Research | |
| 6/24/2024 | Hold | Argus | |
| 5/30/2024 | $54.00 | Sell | Goldman |
DEFA14A - Solventum Corp (0001964738) (Filer)
DEF 14A - Solventum Corp (0001964738) (Filer)
IRANNOTICE - Solventum Corp (0001964738) (Filer)
ST. PAUL, Minn., April 17, 2025 /PRNewswire/ -- Solventum (NYSE:SOLV) will release its first quarter fiscal 2025 financial results on Thursday, May 8, 2025, after the U.S. financial markets close. After the release, Solventum management will host a webcast to discuss the results and its business. Other forward-looking and material information may also be discussed during the webcast. Earnings webcast details: Date: Thursday, May 8, 2025 Time: 3:30 p.m. CST / 4:30 p.m. EST Location: https://investors.solventum.com U.S. dial-in +1 (800) 715-9871 International dial-in: +1 (646
Reported sales increased 1.9% to $2.074 billion; organic sales increased 2.3%GAAP diluted Earnings Per Share (EPS) of $0.17; adjusted EPS1 of $1.41Generated $219 million in cash from operations; free cash flow of $92 millionIntroduces full-year 2025 organic sales growth, adjusted EPS and free cash flow guidanceST. PAUL, Minn., Feb. 27, 2025 /PRNewswire/ -- Solventum (NYSE:SOLV) today reported financial results for the fourth quarter ended December 31, 2024. "Solventum executed another quarter of solid performance, enabling us to deliver full year 2024 at the high end of our ex
Company to host an Investor Day in March 2025ST. PAUL, Minn., Jan. 30, 2025 /PRNewswire/ -- Solventum (NYSE:SOLV) will release its fourth quarter fiscal year 2024 financial results on Thursday, February 27, 2025, after the U.S. financial markets close. Following the release, Solventum management will host a webcast to discuss the results and fiscal year 2025 outlook. Other forward-looking and material information may also be discussed during the webcast. Earnings webcast details: Date: Thursday, February 27, 2025 Time: 3:30 p.m. CST / 4:30 p.m. EST Location: https://investor
4 - Solventum Corp (0001964738) (Issuer)
4 - Solventum Corp (0001964738) (Issuer)
4 - Solventum Corp (0001964738) (Issuer)
SC 13G/A - Solventum Corp (0001964738) (Subject)
SC 13G/A - Solventum Corp (0001964738) (Subject)
ST. PAUL, Minn., April 17, 2025 /PRNewswire/ -- Solventum (NYSE:SOLV) will release its first quarter fiscal 2025 financial results on Thursday, May 8, 2025, after the U.S. financial markets close. After the release, Solventum management will host a webcast to discuss the results and its business. Other forward-looking and material information may also be discussed during the webcast. Earnings webcast details: Date: Thursday, May 8, 2025 Time: 3:30 p.m. CST / 4:30 p.m. EST Location: https://investors.solventum.com U.S. dial-in +1 (800) 715-9871 International dial-in: +1 (646
In this first-of-its-kind partnership for its Dental Solutions business, Solventum, formerly 3M Health Care, is striving to focus on longevity and durability of permanent same-day restorative dental offerings, reaffirming its commitment to solving industry's toughest problems Partnership aims to integrate innovative new material science and disruptive technology like chairside 3D printing to optimize workflows, enhance procedural efficiency and benefit both patients and practitioners ST. PAUL, Minn., March 25, 2025 /PRNewswire/ -- Solventum (NYSE:SOLV), the leader in dental composites and restorative dentistry, today announced a strategic partnership with SprintRay, a leading provider of ch
Provides 2028 Targets for Revenue Growth, Margin Expansion, and Free Cash Flow ST. PAUL, Minn., March 20, 2025 /PRNewswire/ -- Solventum (NYSE:SOLV) today hosts its 2025 Investor Day and will outline strategic priorities for the Company, its business segments, and its long-range plan (LRP) to drive growth and value creation. "Solventum has tremendous potential, with attractive businesses, large and growing markets, and highly regarded brands. We have undertaken a significant transformation to unlock the potential of our Medical Surgical, Dental Solutions, and Health Informatio
BOSTON, Feb. 11, 2025 (GLOBE NEWSWIRE) -- Ampersand Biomedicines, a multi-product platform company developing smarter medicines that act specifically at the site of disease and nowhere else, today announced the appointment of Elizabeth Mily to its Board of Directors as Independent Director. A highly respected healthcare and financial industry veteran with more than 30 years of experience, Mily brings extensive expertise in corporate strategy, business development and investment leadership to Ampersand as it advances its Address, Navigate, Determine (AND)™ Platform to develop programmed biologics. "We are thrilled to welcome Elizabeth to Ampersand's Board as we leverage our AND Platform to
Former Bristol Myers Squibb, Goldman Sachs, and Barclays executive brings deep expertise in corporate strategy, partnership development, public and private financial markets, and management as the organization evolves its leadership and investment strategy Appointment signals plans to capitalize on previous success and maximize impact by expanding equity investments and partnerships with venture capital, large biopharma, and key foundations with a proven team leader and dealmaker BOSTON, Jan. 8, 2025 /PRNewswire/ -- The T1D Fund, an impact investment fund with a focus on accelerating life-changing solutions to treat, prevent, and cure type 1 diabetes (T1D), today announced it appointed Eliza
ST. PAUL, Minn., Oct. 10, 2024 /PRNewswire/ -- Solventum (NYSE:SOLV) announced today that Dr. Ryan Egeland, MD, has been named chief medical officer. Dr. Egeland is responsible for leading Solventum's Global Medical and Clinical Affairs team, amplifying the voice of clinicians and patients. In this role, he will focus on fostering industry collaboration and identifying innovation and market expansion opportunities at the intersection of scientific rigor, clinical need, and commercial practicality. Dr. Egeland will report to Chris Barry, executive vice president and group presi
Mizuho initiated coverage of Solventum Corporation with a rating of Neutral and set a new price target of $70.00
Stifel initiated coverage of Solventum Corporation with a rating of Buy and set a new price target of $82.00
Piper Sandler initiated coverage of Solventum Corporation with a rating of Neutral and set a new price target of $71.00